STAT+: Purdue says most creditors voted in favor of contentious bankruptcy plan
In an apparent victory for Purdue Pharma, preliminary voting shows most creditors are in favor…
Category: Pharmalot
STAT+: Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules
Good morning. Elizabeth Cooney sitting in for Ed Silverman on what from here looks like…
STAT+: Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs
In the latest look at clinical trial transparency, a new analysis found that only 26%…
STAT+: Pharmalittle: Biogen defends its controversial Alzheimer’s drug; critics pan Pfizer plan for Covid-19 shot production in Africa
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: Pfizer looks to widen access to Covid-19 vaccine in Africa, but advocates say it doesn’t go far enough
Pfizer (PFE) and BioNTech (BNTX) moved Wednesday to widen access to Covid-19 vaccines by striking…
States reach $26 billion deal with three wholesalers and J&J to end opioid lawsuits
Three of the largest pharmaceutical wholesalers and a major drug maker reached a $26 billion…
STAT+: Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: FDA plans to study whether pharma reps at conference exhibit booths are telling the truth
Pandemics aside, medical conferences are popular destinations for doctors, who are barraged with information about…
STAT+: Three pharma wholesalers reach a $1.1 billion deal with New York over the opioid crisis
Three of the largest pharmaceutical wholesalers in the U.S. agreed to pay up to $1.1…
STAT+: As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional
In harsh words, the U.S. Department of Justice castigated Purdue Pharma’s proposed bankruptcy plan as…
STAT+: Pharmalittle: Wholesalers near deal over opioid litigation; pharma gives $67,400 to Peters for trying to torpedo drug pricing bill
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Advocates urge Biden to name patent office director that could transform drug pricing
As the White House readies to name a new head of the U.S. Patent &…
STAT+: Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in the Netherlands have fined a drug maker $23 million for years of…
STAT+: Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 vaccine; CT attorney general calls some Sacklers ‘entitled thugs’
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Amid Purdue bankruptcy talks, Connecticut attorney general accuses some Sacklers of intimidation
In the latest drama surrounding Purdue Pharma, Connecticut Attorney General William Tong lashed out at…
STAT+: Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug
Happy Friday, everyone! This is Elizabeth Cooney, sitting in for Ed Silverman this fine morning….
STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
A prominent panel of medical experts unanimously voted that there is no evidence to suggest…
STAT+: U.K. issues record fine to drug makers for price gouging and collusion schemes
After a lengthy investigation, the U.K. antitrust regulator has fined several drug makers a record-setting…
STAT+: Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug
Top of the morning to you and a fine one, it is. Moderate temperatures and…
STAT+: FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug
In an embarrassing rebuke, the Food and Drug Administration has scolded Amgen (AMGN) over a…
STAT+: Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit
A federal judge dropped allegations that three drug makers engaged in antitrust practices by scheming…
.jpg)
STAT+: Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year
A pricey new Alzheimer’s drug already mired in controversy could cost Medicaid anywhere from $720…
STAT+: Pharmalittle: Medicare starts coverage review for Biogen Alzheimer’s drug; U.S. needs more data before deciding on Covid booster shot
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Biden’s executive order would pause a Trump rule forbidding march-in rights to lower drug costs
In a little-noticed move, the Biden administration has hit the pause button on a rule…
STAT+: Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks
A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in…
STAT+: Pharmalittle: U.S. officials and Pfizer to meet over Covid-19 booster shots; FDA full approval for vaccines may not be a game changer
Good morning, everyone, and nice to see you again after we took an extended break….
STAT+: Pharmalittle: Even FDA officials balked at the broad Aduhelm label; CDC and FDA are dubious about Covid booster shots
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT+: FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned
In a bid to calm anxious patients, the Food and Drug Administration has extended the…
.jpg)
STAT+: House Democrats say pharma stock buybacks and dividends exceed R&D spending
A Congressional committee released a report on Thursday showing the 14 largest drug makers spent…
STAT+: Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs
A former Genentech principal scientist and her husband were convicted of stealing trade secrets and…
STAT+: Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval
Fifteen states have agreed to drop their long-standing objections to a contentious bankruptcy plan to…
STAT+: Pharmalittle: In rare move, FDA revises label for Biogen Alzheimer’s drug; former compounding exec gets added jail time
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: Pharmalittle: Another lawmaker calls for probe of FDA approval of Alzheimer’s drug; Roche urged to lower price of Covid-19 therapy
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19
After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors…
STAT+: Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits
Good morning, everyone, and welcome to another working week, albeit an abbreviated one on this…
STAT+: Regulators in many European countries fail to ensure clinical trial data are available
Amid ongoing concerns over clinical trial transparency, a new report finds “notable gaps” in the…
STAT+: Purdue wants to shower employees with nearly $35 million in different kinds of bonuses
As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug…
STAT+: Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders
And so, another working week will soon draw to a close. Not a moment too…
STAT+: U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing
In the latest bid to compare drug costs, a new study finds that prices for…
STAT+: Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: Mallinckrodt cleared to sell a rare disease drug to a startup, but parents worried over ongoing access
A federal bankruptcy court judge has approved the sale of a rare disease drug to…
STAT+: Pharmalittle: Most doctors disagree with FDA approval of the Alzheimer’s drug; women underrepresented in life sciences C-suites
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year
The controversial new Alzheimer’s drug from Biogen (BIIB) would be cost-effective only if priced between…
STAT+: Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug
A majority of U.S. physicians disagree with the decision by the Food and Drug Administration…
STAT+: Pharmalittle: How Biogen and FDA formed a back channel to push an Alzheimer’s drug; Sanofi to dive into mRNA vaccine development
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Amid a national outcry over the cost of insulin, Walmart (WMT) plans to sell a…
STAT+: Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?
Gilead Sciences (GILD) released top-line trial data for its Yescarta treatment that may allow the…
STAT+: Pharmalittle: Biogen Alzheimer’s drug will cost Medicare how much? Intellia data suggest a first for genome editing
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…